{
    "id": 8873,
    "fullName": "RNF43 inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "RNF43 inact mut indicates that this variant result in a loss of function of the Rnf43 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 54894,
        "geneSymbol": "RNF43",
        "terms": [
            "RNF43",
            "RNF124",
            "SSPCS",
            "URCC"
        ]
    },
    "variant": "inact mut",
    "createDate": "07/08/2015",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11118,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXC004 inhibited tumor growth in patient-derived xenograft models of gastric cancer harboring RNF43 loss-of-function mutations (J Clin Oncol 35, 2017 (suppl; abstr e14094)).",
            "molecularProfile": {
                "id": 8767,
                "profileName": "RNF43 inact mut"
            },
            "therapy": {
                "id": 5865,
                "therapyName": "RXC004",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9091,
                    "pubMedId": null,
                    "title": "Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_193236.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17965,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 8767,
                "profileName": "RNF43 inact mut"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11117,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXC004 inhibited tumor growth in cell line xenograft models of pancreatic cancer harboring RNF43 loss-of-function mutations (J Clin Oncol 35, 2017 (suppl; abstr e14094)).",
            "molecularProfile": {
                "id": 8767,
                "profileName": "RNF43 inact mut"
            },
            "therapy": {
                "id": 5865,
                "therapyName": "RXC004",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9091,
                    "pubMedId": null,
                    "title": "Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_193236.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17966,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 8767,
                "profileName": "RNF43 inact mut"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8767,
            "profileName": "RNF43 inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 8720,
                    "name": "WNT Inhibitor",
                    "profileName": "RNF43 inact mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}